Related Experiment Video
Updated: Apr 29, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Targeting endoplasmic reticulum stress and YAP/TAZ-SMAD1/5 signaling to ameliorate endothelial dysfunction in
Yan Zhou1,2, Yifan Yang1, Yuehan Wang1
1The State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
Abstract:
YAP/TAZ and SMAD1/5 signaling modulate atherosclerosis. These involvements in diabetes-associated endothelial dysfunction remain unexplored, thereby being investigated from different endothelial cells and a total of 102 mice in the current study. Male C57BL/6 mice were fed a high-fat diet (45% kcal% fat, 15 weeks) and orally administered with endoplasmic reticulum (ER) stress alleviator 4-phenylbutyric acid (100 mg·kg-1·d-1) and jatrorrhizine (50 mg·kg-1·d-1) for 5 weeks. Endothelial cells were cultured with high glucose, ER stress inducer tunicamycin, ER stress alleviators, YAP inhibitor simvastatin, or jatrorrhizine. The mouse aorta was divided into the aortic arch and thoracic aorta regions to investigate the regional difference. Treatment with PBA and jatrorrhizine ameliorated endothelium-dependent relaxations as well as inhibited ER stress, YAP/TAZ-SMAD1/5 signaling and oxidative stress in aortas. Phosphorylation of YAP/TAZ was highly expressed in the thoracic aorta but low in the aortic arch. On the other hand, phosphorylation of SMAD1/5 was upregulated in the inner curvature of the aortic arch but downregulated in the thoracic aorta. In HUVECs, ER stress alleviators significantly inhibited YAP/TAZ-SMAD1/5 signaling and increased NO bioavailability, but the YAP inhibitor did not suppress ER stress. Inhibition of YAP/TAZ downregulated SMAD1/5 signaling under high glucose stimulation, followed by the Akt/eNOS pathway. YAP/TAZ directly interacts with SMAD1/5, and their binding is significantly enhanced under high-glucose conditions. A natural compound, jatrorrhizine, was identified to inhibit YAP/TAZ-SMAD1/5 signaling and protect vascular function in diabetes. To conclude, ER stress activates YAP/TAZ and SMAD1/5 signaling, resulting in endothelial dysfunction in diabetes. Inhibition of YAP/TAZ-SMAD1/5, such as by ER stress alleviators and natural product jatrorrhizine, ameliorates endothelial dysfunction associated with diabetes. These findings support the cross-talk between ER stress and YAP/TAZ-SMAD1/5 as well as their potential as therapeutic targets.
Insights
Endoplasmic reticulum stress activates YAP/TAZ and SMAD1/5 signaling, causing endothelial dysfunction in diabetes. Inhibiting this pathway with ER stress alleviators or jatrorrhizine improves vascular function.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Endothelial Cell Biology
Background:
- Diabetes is associated with endothelial dysfunction, a key factor in atherosclerosis.
- The roles of YAP/TAZ and SMAD1/5 signaling in diabetes-related endothelial dysfunction are not fully understood.
- Endoplasmic reticulum (ER) stress is implicated in diabetic complications.
Purpose of the Study:
- To investigate the involvement of YAP/TAZ and SMAD1/5 signaling in diabetes-associated endothelial dysfunction.
- To explore the therapeutic potential of ER stress alleviators and natural compounds like jatrorrhizine.
- To elucidate the interplay between ER stress and YAP/TAZ-SMAD1/5 signaling in the diabetic vasculature.
Main Methods:
- Utilized a mouse model of diet-induced diabetes and endothelial dysfunction.
- Administered ER stress alleviators (4-phenylbutyric acid) and jatrorrhizine to mice and cultured endothelial cells.
- Analyzed signaling pathways (YAP/TAZ, SMAD1/5, Akt/eNOS), ER stress markers, oxidative stress, and vascular function (endothelium-dependent relaxations).
- Investigated regional differences in signaling within the mouse aorta.
Main Results:
- Treatment with 4-phenylbutyric acid and jatrorrhizine ameliorated endothelial dysfunction, reduced ER stress, and inhibited YAP/TAZ-SMAD1/5 signaling and oxidative stress.
- YAP/TAZ phosphorylation showed regional differences in the aorta, as did SMAD1/5 phosphorylation.
- ER stress alleviators inhibited YAP/TAZ-SMAD1/5 signaling and increased NO bioavailability in endothelial cells.
- YAP/TAZ directly interacts with SMAD1/5, with enhanced binding under high-glucose conditions.
Conclusions:
- ER stress activates YAP/TAZ and SMAD1/5 signaling, leading to endothelial dysfunction in diabetes.
- Inhibition of YAP/TAZ-SMAD1/5 signaling, via ER stress alleviators or jatrorrhizine, ameliorates diabetes-associated endothelial dysfunction.
- The cross-talk between ER stress and YAP/TAZ-SMAD1/5 signaling presents potential therapeutic targets for diabetic vascular complications.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Diabetic Retinopathy
Type II Diabetes II: Pathophysiology
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System